Romatolojide Kullanılan Biyolojik Tedaviler ve Hemşirelik Bakımı

Year 2022, , 45 - 52, 20.04.2022

Ayten Dağ

https://doi.org/10.48071/sbuhemsirelik.1081310

Abstract

Biyolojik ilaçların romatolojik hastalıklarda hastalık aktivitesinin baskılanması, hastalığa bağlı oluşan yapısal hasarın önlenmesi, yaşam kalitesinin artırılmasında ve iş gücü kaybının önlenmesinde önemli bir etkisi vardır. Daha etkili biyolojik tedavi arayışları devam etmekte ve halen yeni ilaçlar denenmektedir. Biyolojik tedavilerin yaygınlaşmasıyla birlikte hemşirelerin hasta değerlendirmesi, eğitimi, ilaç yönetimi ve izlemi konusunda önemli rolleri olmaktadır. Biyolojik ilaç tedavisine yönelik hemşirelik yönetimi ile ilgili kanıta dayalı araştırmalar ve standart rehberlerin oluşturulmasına ihtiyaç artmaktadır. Bu derleme ile romatoloji alanında kullanılan biyolojik ilaçlar ve biyolojik ilaç tedavisi alan bireylere yönelik hemşirelik bakımı ele alınmıştır.

Keywords

biyolojik tedavi, hemşirelik bakımı, romatoloji

Supporting Institution

Destekleyen kurum bulunmamaktadır

Biological Therapies Used in Rheumatology and Nursing Care

Abstract

Biological drugs had an important effect on suppressing disease activity in rheumatological diseases, preventing structural damage due to the disease, increasing the quality of life and preventing loss of workforce. The search for more effective biological treatments continues and new drugs are still being tried. With the spread of biological treatments, nurses have important roles in patient evaluation, education, drug management and follow-up. There is an increasing need for evidence-based research and standard guidelines on nursing management for biological drug therapy. In this review, we discussed biological drugs used in the field of rheumatology and nursing care for individuals receiving biological drug therapy.

Keywords

Biological, biological therapy, nursing care, rheumatology

References

• Akyar, İ. (2015). Romatoloji Hemşireliği Rol ve Sorumluluklara Genel Bakış. F, Çınar., M, Çınar., S, Yılmaz ve H, Erdem. (Ed.), Romatoloji Hemşireliği ve Klinik Uygulamalar içinde (s. 1-6). İstanbul: Deomed Yayıncılık.
• Aldredge, L. M., & Young, M. S. (2016). Providing guidance for patients with moderate-to-severe psoriasis who are candidates for biologic therapy: Role of the nurse practitioner and physician assistant. Journal of the Dermatology Nurses' Association, 8(1), 14–26. doi:10.1097/JDN.0000000000000185.
• American College of Rheumatology (ACR). (2020). Tumor Necrosis Factor (TNF) inhibitors. Retrieved from (02.01.2022): https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Treatments/TNF-Inhibitors.
• Arslan, D. E., Şentürk, S., ve Akça, N.K. (2021). Biyolojik ajan kullanan romatoid artritli hastaların ilaç tedavisine uyumu ve etkileyen faktörler. Göbeklitepe International Journal of Health Sciences, 4(5),87-95.
• Basit, G. (2020). Bakımın rehberi: hemşirelik süreci. Genel Sağlık Bilimleri Dergisi, 2(2), 77-90.
• Beringer, A., Noack, M., & Miossec, P. (2016). IL-17 in chronic inflammation: from discovery to targeting. Trends In Molecular Medicine, 22(3), 230-241. doi:10.1016/j.molmed.2016.01.001
• Buch, M. H., Smolen, J. S., Betteridge, N., Breedveld, F. C., Burmester, G., Dörner, T., … Emery, P. (2011). Updated consensus statement on the use of rituximab in patients with Rheumatoid Arthritis. Annals of The Rheumatic Diseases, 70(6), 909–920. doi:10.1136/ard.2010.144998.
• Della-Torre, E., Lanzillotta, M., Campochiaro, C., Cavalli, G., De Luca, G., Tomelleri, A., … Dagna, L. (2021). Respiratory impairment predicts response to IL-1 and IL-6 blockade in COVID-19 patients with severe Pneumonia and Hyper-Inflammation. Frontiers in Immunology, 12, 675678. doi:10.3389/fimmu.2021.675678.
• Deodhar, A., Van der Heijde, D., Gensler, L. S., Kim, T. H., Maksymowych, W. P., Østergaard, M. … COAST-X Study Group (2020). Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet (London, England), 395(10217), 53–64. doi:10.1016/S0140-6736(19)32971-X
• Esatoğlu, S. N. (2021). Romatolojide biyolojik ilaçlar ve tedavi prensipleri. V. Hamuryudan (Ed.), Cerrahpaşa romatoloji notları içinde (s. 253-258.). İstanbul: Nobel Tıp Kitabevleri.
• Fadıloğlu, Ç., Nazmiye, Ç. G., ve Öksel, E. (2012). Kanser tedavisinde güncel yaklaşım: biyoterapi ve hemşirelik yönetimi. Ege Üniversitesi Hemşirelik Fakültesi Dergisi 28(1), 91-103.
• Götestam Skorpen, C., Hoeltzenbein, M., Tincani, A., Fischer-Betz, R., Elefant, E., Chambers, C., … Østensen, M. (2016). The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Annals of the Rheumatic Diseases, 75(5), 795–810. doi:10.1136/annrheumdis-2015-208840.
• Grisar, J. (2015). Biologicals and how they revolutionized rheumatology. Wiener Medizinische Wochenschrift (1946), 165(1-2), 1–2. doi:10.1007/s10354-015-0343-z.
• Gülbezer, E. E., ve Keser, G. (2017). Biyolojik tedaviler. Ulusal Romatoloji Dergisi (RAED), 9.
• Hayashi, T. (2013). Golimumab. Nihon Rinsho, 71(7), 1227-1231.
• Herdman, T. H. (2018). Hemşirelik tanıları tanımlar ve sınıflandırma 2015-2017. (R. Acaroğlu, Çev.). İstanbul: Nobel Tıp Kitabevleri.
• Holroyd, C. R., Seth, R., Bukhari, M., Malaviya, A., Holmes, C., Curtis, E., … Ledingham, J. (2019). The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis-Executive summary. Rheumatology (Oxford, England), 58(2), 220–226. doi:10.1093/rheumatology/key207.
• Kaiser, C., Knight, A., Nordström, D., Pettersson, T., Fransson, J., Florin-Robertsson, E., & Pilström, B. (2012). Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatology International, 32(2), 295–299. doi:10.1007/s00296-011-2096-3.
• Koike, T., Harigai, M., Inokuma, S., Ishiguro, N., Ryu, J., Takeuchi, T., … Yamanaka, H. (2014). Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. The Journal of Rheumatology, 41(1), 15–23. doi:10.3899/jrheum.130466.
• Lee, A., & Scott, L. J. (2020). Certolizumab Pegol: A review in moderate to severe Plaque Psoriasis. BioDrugs, 34(2), 235-244. doi:10.1007/s40259-020-00416-z Lempp, H., Baggott, R., Scott, D. L., Parker, L., Bosworth, A., Georgopoulou, S., & Firth, J. (2020). The value, impact and role of nurses in rheumatology outpatient care: Critical review of the literature. Musculoskeletal care, 18(3), 245–255. doi:10.1002/msc.1467.
• Lenz, H. J. (2007). Management and preparedness for infusion and hypersensitivity reactions. The Oncologist, 12(5), 601-609. doi:10.1634/theoncologist.12-5-601 Lichtenstein, L., Ron, Y., Kivity, S., Ben-Horin, S., Israeli, E., Fraser, G. M., … Weiss, B. (2015). Infliximab-related infusion reactions: systematic review. Journal of Crohn's & Colitis, 9(9), 806–815. doi:10.1093/ecco-jcc/jjv096
• Maggi, E., Vultaggio, A., & Matucci, A. (2011). Acute infusion reactions induced by monoclonal antibody therapy. Expert Review of Clinical Immunology, 7(1), 55-63. doi:10.1586/eci.10.90
• Melo, A. T., Campanilho-Marques, R., & Fonseca, J. E. (2021). Golimumab (anti-TNF monoclonal antibody): where we stand today. Human Vaccines & Immunotherapeutics, 17(6), 1586-1598. doi:10.1080/21645515.2020.1836919
• Navarro-Millán, I., Singh, J. A., & Curtis, J. R. (2012). Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clinical Therapeutics, 34(4), 788-802. doi:10.1016/j.clinthera.2012.02.014.
• Pan, A., & Gerriets, V. (2021). Etanercept. In StatPearls. StatPearls Publishing.
• Prieto-Peña, D., & Dasgupta, B. (2020). Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update. Polish Archives of Internal Medicine, 131, 171-181. doi:10.20452/pamw.15438
• Rombouts, M. D., Swart, E. L., Van den Eertwegh, A., & Crul, M. (2020). Systematic review on infusion reactions to and infusion rate of monoclonal antibodies used in cancer treatment. Anticancer Research, 40(3), 1201–1218. doi:10.21873/anticanres.14062
• Sağ, S., ve Nas, K. (2017). Romatolojide biyolojik ajanların kullanımı. Online Türk Sağlık Bilimleri Dergisi, 2(2), 34-45.
• Shetty, A., Hanson, R., Korsten, P., Shawagfeh, M., Arami, S., Volkov, S., … Sweiss, N. J. (2014). Tocilizumab in the treatment of Rheumatoid Arthritis and beyond. Drug design, development and therapy, 8, 349–364. doi:10.2147/DDDT.S41437
• Sierakowska, M., Sierakowski, S., Lewko, J., Jankowiak, B., Kowalczuk, K., & Krajewska-Kułak, E. (2007). Nursing problems of patients with systemic sclerosis. Advances in Medical Sciences, 52(1), 147–152.
• Thomaidou, E., & Ramot, Y. (2019). Injection site reactions with the use of biological agents. Dermatologic Therapy, 32(2), e12817. doi:10.1111/dth.12817
• Tleyjeh, I. M., Kashour, Z., Damlaj, M., Riaz, M., Tlayjeh, H., Altannir, M., … Kashour, T. (2021). Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Clinical microbiology and infection : The official publication of the European Society of Clinical Microbiology and Infectious Diseases, 27(2), 215–227. doi:10.1016/j.cmi.2020.10.036.
• Tufan, A., & Lachmann, H. (2020). Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review. Turkish Journal of Medical Sciences, 50(SI-2), 1591-1610. doi:10.3906/sag-2008-11.
• Vivar, N., & Van Vollenhoven, R. F. (2014). Advances in the treatment of rheumatoid arthritis. F1000prime reports, 6. doi:10.12703/P6-31
• Yazıcı A., ve Çefle A. (2014). Biyolojik tedaviler ve gebelik. Ulusal Romatoloji Dergisi (RAED), 6(1), 33-35. doi:10.2399/raed.14.2193